You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Test volume growth for its Panorama NIPT and Horizon carrier screening tests drove its revenues gains year over year.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Unilabs has licensed the rights to develop, validate, and run Natera's Panorama NIPT technology out of its own laboratories.
Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
Although Sequenom had garnered support from a diverse range of groups who wanted clarity on patent eligibility, the Supreme Court denied the petition.
Genomed, based in Warsaw, offers sequencing-based diagnostic and research services and brought BGI's noninvasive prenatal NIFTY test in house last year.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
The company's first quarter revenues jumped due to an increase in NIPT and carrier screening testing volumes.
The company has been quietly working on a fully automated NIPT for trisomies 21, 13, and 18 that requires neither next-gen sequencing nor microarray technology.